Reviewing the Advancements of siRNA-based Therapeutics to Treat Complement-Mediated Kidney Disease
10:15 am - Tuesday 2nd December 2025
- Highlighting the potential of RNA interference-based therapeutics in modulating complement-driven kidney diseases and offer insights into their mechanism of action
- Exploring the unique advantages of siRNA technology for complement inhibition in kidney disease, such as potentially targeted delivery and sustained effect
- Touching upon challenges and best practices in conducting large Phase 3 trials